drugset / Trial / NCT04147286
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
Phase 2/3
Recruiting
220 enrolled
University of Cape Town
University of Bern · collabUniversity of Namibia · collabUniversity of Stellenbosch · collabUniversity of Zurich · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.
Timeline
- Start
- 2020-07-14
- Primary completion
- 2025-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 40 mg | Oral |